In the market landscape of Smoking Cessation and Nicotine Addiction, an impressive surge is expected during the study period spanning 2020 to 2034, according to latest report titled “Smoking Cessation and Nicotine Addiction Market Insights, Epidemiology and Market Forecast 2034” from DelveInsight.
The Smoking Cessation and Nicotine Addiction market report sheds light on Smoking Cessation and Nicotine Addiction current treatment practices, upcoming drugs in the Smoking Cessation and Nicotine Addiction pipeline, market shares of individual therapies, and the anticipated trajectory of the Smoking Cessation and Nicotine Addiction market size from 2020 to 2034 across the 7MM (the United States, the EU-4 comprising Italy, Spain, France, and Germany, the United Kingdom, and Japan).
Key highlights from the Smoking Cessation and Nicotine Addiction Market Report:
-
The majority of prevalent cases of smoking cessation were estimated in the United States, followed by the EU4, the UK, and Japan, with the highest rates of tobacco use observed in the EU4 and the UK within these regions.
-
In 2023, the smoking cessation and nicotine addiction treatment market was largest in the United States, valued at approximately USD 1,472 million, while Germany recorded the smallest market size at USD 46 million. This market is expected to grow significantly by 2034.
-
The overall market for smoking cessation and nicotine addiction treatments is forecasted to expand during the period from 2024 to 2034, driven by emerging therapies such as cytisinicline, AXS-05, and NFL-101.
-
In 2023, tobacco use in the US was more prevalent among males, with around 31,040 thousand cases, compared to 19,846 thousand cases in females.
Smoking Cessation and Nicotine Addiction Overview
Nicotine dependence is a complex condition that involves behavioral, cognitive, and physiological aspects resulting from repeated tobacco use. It is characterized by a strong craving for tobacco, difficulty in controlling its use, continued use despite negative consequences, prioritizing tobacco over other activities, increased tolerance, and withdrawal symptoms. Tobacco is the primary source of nicotine, typically consumed through smoking, chewing, or snorting, with cigarette smoking being the most common and harmful method. Contributing factors to nicotine addiction include poor enforcement of smoking bans, lack of education, insufficient motivation to quit, inadequate training among mental health professionals, and limited treatment options, particularly in underdeveloped countries. Chronic tobacco use leads to neuroadaptation and tolerance, with withdrawal symptoms like irritability, anxiety, increased appetite, and dysphoria, which are further reinforced by conditioning. These factors contribute to the significant global health burden of tobacco addiction.
Nicotine and its metabolites, such as cotinine and anabasine, can be detected in urine and blood tests to monitor compliance with withdrawal therapy or assess nicotine toxicity. Another method for measuring nicotine use is carbon monoxide (CO) levels, which correlate with cotinine levels. Several questionnaires, such as the Fagerström Test for Nicotine Dependence, the Wisconsin Inventory of Smoking Dependence and Motives, and the Smokeless Tobacco Dependence Scale, are used to assess the severity of nicotine dependence.
Effective treatment for smoking cessation and nicotine addiction typically involves a combination of pharmacotherapy, behavioral therapy, and support systems. Pharmacotherapies include nicotine replacement therapies (NRTs) like patches, gum, and lozenges, which deliver controlled doses of nicotine to reduce withdrawal symptoms and cravings. Medications such as varenicline and bupropion target neural pathways to decrease the pleasure associated with smoking and alleviate withdrawal effects. Behavioral therapies, including cognitive-behavioral therapy (CBT) and motivational interviewing, address the psychological components of addiction by helping individuals develop coping strategies, set goals, and enhance motivation to quit. Support systems, including counseling, support groups, and helplines, provide ongoing encouragement and resources, which significantly improve quit rates. Combining these approaches increases the likelihood of successful smoking cessation by addressing both the physiological and psychological aspects of nicotine dependence.
Smoking cessation and nicotine addiction epidemiology insights:
-
According to DelveInsight estimates, in 2023, the EU4 and the UK had the highest prevalence of tobacco use, with approximately 63,953 thousand cases, followed by the United States with around 50,886 thousand cases, and Japan with about 20,185 thousand cases. These numbers are projected to decline in the US, EU4, the UK, and Japan by 2034.
-
In 2023, among the EU4 and the UK, Germany had the highest prevalence of tobacco use, with approximately 18,101 thousand cases, followed by France with around 16,429 thousand cases. The UK had the lowest prevalence of tobacco use in both the EU4 and UK regions as well as the 7MM, with approximately 8,788 thousand cases.
-
Tobacco use is predominantly male-dominant. In 2023, around 59% of the prevalent tobacco use cases in the 7MM were among males, while approximately 41% were among females.
Driving Forces Behind the Smoking Cessation and Nicotine Addiction Market Growth
Increase in the patient pool, expected entry of emerging therapies will boost the Smoking Cessation and Nicotine Addiction market during the forecast period (2023–2034).
Discover the Anticipated Evolution and Growth of the Market @ Smoking Cessation and Nicotine Addiction Therapeutics Market Forecast
Therapeutic Advancements and Emerging Treatments:
-
Smoking Cessation and Nicotine Addiction Clinical Trial Progression: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2034. Pioneering companies, including Axsome Therapeutics, Achieve Life Sciences, NFL Biosciences SAS, and others, are actively engaged in developing novel drugs for potential market entry.
-
Smoking Cessation and Nicotine Addiction Innovative Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Smoking Cessation and Nicotine Addiction. Therapies such as AXS-05, Cytisinicline, NFL-101, and others are driving the Smoking Cessation and Nicotine Addiction market.
Smoking Cessation and Nicotine Addiction Market
Effective treatments for tobacco cessation include both behavioral therapies and FDA-approved medications, with a range of products and services available to support individuals trying to quit smoking. These treatments include smoking alternatives that are not specifically indicated for cessation, as well as FDA-approved pharmacotherapies, such as various forms of nicotine replacement therapies (NRTs) in the form of transdermal patches, gums, nasal sprays, oral inhalers, and lozenges.
The US FDA has approved two smoking cessation products that do not contain nicotine: CHANTIX (varenicline tartrate) and ZYBAN (bupropion hydrochloride). Both are prescription-only tablets, and in recent years, generic versions of these drugs have entered the market. These medications are widely available in the US and Europe, while in Japan, varenicline (sold as CHAMPIX), NRT, and some off-label therapies are used for smoking cessation. However, bupropion-SR is not licensed in Japan for this purpose.
Key companies, including Achieve Life Sciences (Cytisinicline), Axsome Therapeutics (AXS-05), and NFL Biosciences (NFL-101), are currently evaluating their lead candidates in various stages of clinical development to explore their potential in treating smoking cessation and nicotine addiction.
|
Report Features |
Details |
|
Geography Coverage |
7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] |
|
Study Period |
2020-2034 |
|
Smoking Cessation and Nicotine Addiction Market Size |
USD XX million in 2034 |
|
Key Smoking Cessation and Nicotine Addiction Companies |
Axsome Therapeutics, Achieve Life Sciences, NFL Biosciences SAS, and others. |
Leading Smoking Cessation and Nicotine Addiction Companies and Emerging Drugs: Pioneering companies such as Axsome Therapeutics, Achieve Life Sciences, NFL Biosciences SAS, among others, are actively developing novel drugs for potential entry into the Smoking Cessation and Nicotine Addiction market.
Smoking Cessation and Nicotine Addiction Therapeutic Landscape: Key therapies identified for Smoking Cessation and Nicotine Addiction treatment include AXS-05, Cytisinicline, NFL-101, and more.
For in-depth insights, TOC, access the full report @ Smoking Cessation and Nicotine Addiction Market Outlook 2034
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Smoking Cessation and Nicotine Addiction Market Growth Anticipated by 2034 | Axsome Therapeutics, Achieve Life Sciences, NFL Biosciences SAS, expected to boost the market